Severe Asthma and Biological Therapies: Now and the Future

J Clin Med. 2023 Sep 8;12(18):5846. doi: 10.3390/jcm12185846.


Recognition of phenotypic variability in pediatric asthma allows for a more personalized therapeutic approach. Knowledge of the underlying pathophysiological and molecular mechanisms (endotypes) of corresponding biomarkers and new treatments enables this strategy to progress. Biologic therapies for children with severe asthma are becoming more relevant in this sense. The T2 phenotype is the most prevalent in childhood and adolescence, and non-T2 phenotypes are usually rare. This document aims to review the mechanism of action, efficacy, and potential predictive and monitoring biomarkers of biological drugs, focusing on the pediatric population. The drugs currently available are omalizumab, mepolizumab, benralizumab, dupilumab, and 1ezepelumab, with some differences in administrative approval prescription criteria between the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Previously, we described the characteristics of severe asthma in children and its diagnostic and therapeutic management.

Keywords: 1ezepelumab; benralizumab; biologic; biomarkers; dupilumab; mepolizumab; omalizumab; phenotype; severe asthma.

Publication types

  • Review

Grants and funding

This review received no external funding.